» Authors » Mary D Chamberlin

Mary D Chamberlin

Explore the profile of Mary D Chamberlin including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 26
Citations 246
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Tau S, Chamberlin M, Yang H, Marotti J, Muskus P, Roberts A, et al.
Cancer Res . 2025 Jan; 85(6):1145-1161. PMID: 39777474
Despite adjuvant treatment with endocrine therapies, estrogen receptor-positive (ER+) breast cancers recur in a significant proportion of patients. Recurrences are attributable to clinically undetectable endocrine-tolerant persister cancer cells that retain...
2.
Rubagumya F, Businge L, Hopman W, Murenzi G, Uwimbabazi A, Kwizera V, et al.
Cancer Med . 2024 Nov; 13(21):e70423. PMID: 39530527
Introduction: Head and neck cancer (HNC) is a significant global health burden, with late presentation leading to complex treatment. While human papillomavirus (HPV) infection has been implicated in HNC, data...
3.
Goyal M, Marotti J, Workman A, Tooker G, Ramin S, Kuhn E, et al.
NPJ Breast Cancer . 2024 Oct; 10(1):93. PMID: 39426965
Breast cancer is the most common malignancy affecting women worldwide and is notable for its morphologic and biologic diversity, with varying risks of recurrence following treatment. The Oncotype DX Breast...
4.
Tau S, Chamberlin M, Yang H, Marotti J, Roberts A, Carmichael M, et al.
bioRxiv . 2024 Oct; PMID: 39386444
Statement Of Significance: Endocrine-tolerant persister cancer cells that survive endocrine therapy can cause recurrent disease. Persister cells exhibit increased energetic dependence upon mitochondria for survival and tumor re-growth potential.
5.
Lyons K, Wechsler S, Ejem D, Stevens C, Azuero A, Khalidi S, et al.
JAMA Netw Open . 2024 Mar; 7(3):e242478. PMID: 38517442
Importance: Following treatment, breast cancer survivors face challenges participating in valued activities. Objective: To determine whether a telephone-based coaching rehabilitation intervention enhances activity participation in the year following breast cancer...
6.
Rubagumya F, Wilson B, Manirakiza A, Mutabazi E, Ndoli D, Rudakemwa E, et al.
Oncologist . 2023 Oct; 29(3):e345-e350. PMID: 37897406
Introduction: Cancer is a major public health problem in Rwanda and other low- and middle-income countries (LMICs). While there have been some improvements in access to cancer treatment, the cost...
7.
Cao X, Muller K, Chamberlin M, Gui J, Kaufman P, Schwartz G, et al.
Clin Cancer Res . 2023 Sep; 29(23):4822-4829. PMID: 37733788
Purpose: The aim of this study is to investigate whether near-infrared spectral tomography (NIRST) might serve as a reliable prognostic tool to predict residual cancer burden (RCB) in patients with...
8.
Forbes V, Chamberlin M, Dusabejambo V, Walker T, Bensen S, Haynes N, et al.
Hematol Oncol Clin North Am . 2023 Aug; 38(1):185-197. PMID: 37635048
Our international partnerships have fostered longstanding collaborative relationships leading to the development of unique, locally-designed, and sustainable training programs that serve as models for global health education and cooperation.
9.
Hoxha I, Sadiku F, Hoxha L, Nasim M, Christine Buteau M, Grezda K, et al.
Hematol Oncol Clin North Am . 2023 Aug; 38(1):137-170. PMID: 37635047
Lifestyle factors play a major role in the risk of breast cancer. This review aimed to examine the size of the effect of select lifestyle factors on risk for breast...
10.
Chamberlin M, Ademi Islami D, Barth Jr R, Demaci S
Hematol Oncol Clin North Am . 2023 Jul; 38(1):199-207. PMID: 37442675
Due to the current limited capacity to provide digital mammography-based screening to all women, and the lack of modern surgical oncology methods, mastectomy is still the predominant form of surgical...